All In Biotech

Drug Trial Radar · NCT04149210

FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial

Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,410 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,410

Actual

Start

Aug 19, 2021

Primary completion

Nov 30, 2024

Study completion Nov 30, 2024

Sponsor

Lead sponsor
Massachusetts Eye and Ear InfirmaryAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Pennsylvania; London School of Hygiene and Tropical Medicine; Berhan Public Health and Eye Care Consultancy PLC; The Fred Hollows Foundation, Ethiopia; The Fred Hollows Foundation, Australia
First posted
Nov 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims : * To assess the efficacy of fluorometholone 0.1% one drop twice daily for four weeks in reducing the incidence of post-operative trachomatous trichiasis (TT) when given as adjunctive therapy with TT surgery in the programmatic setting * To assess whether such treatment is sufficiently safe for wide-scale implementation in TT programs. * To estimate the costs of adding fluorometholone 0.1% treatment to TT surgery per case of postoperative TT averted, and to characterize the value of such treatment under a range of plausible health economic circumstances

Conditions

  • Trachomatous Trichiasis (TT)
  • Eye Diseases
  • Eyelid Diseases
  • Trachomatous
  • Trichiasis

Interventions

  • Fluorometholone 0.1% Oph SuspDrug

    fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.

  • Artificial TearsDrug

    Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Postoperative TT by One Year, as Determined by Trained Study Team MembersTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oromia Health Bureau

    Addis Ababa, Addis Ababa, Ethiopia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.